Immuneering Key Executives
This section highlights Immuneering's key executives, including their titles and compensation details.
Find Contacts at Immuneering
(Showing 0 of )
Immuneering Earnings
This section highlights Immuneering's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
$1.45
Stock Price
$52.18M
Market Cap
66
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for Immuneering, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $316.95K | $2.08M | $2.31M |
| Cost of Revenue | $- | $764.14K | $158.12K | $1.15M | $1.28M |
| Gross Profit | $- | $-764.14K | $158.83K | $926.89K | $1.03M |
| Gross Profit Ratio | 0.00% | - | 50.11% | 44.56% | 44.61% |
| Research and Development Expenses | $47.96B | $41.40M | $36.27M | $26.54M | $15.00M |
| General and Administrative Expenses | $16.08B | $16.76M | $15.61M | $8.27M | $3.11M |
| Selling and Marketing Expenses | $- | $-511.87K | $- | $- | $- |
| Selling General and Administrative Expenses | $16.08B | $16.25M | $15.61M | $8.27M | $3.11M |
| Other Expenses | $29.27M | $- | $30.05K | $-127.06K | $- |
| Operating Expenses | $64.07B | $57.65M | $51.90M | $34.81M | $18.11M |
| Cost and Expenses | $- | $58.41M | $52.06M | $35.97M | $19.39M |
| Interest Income | $2.59B | $3.61M | $1.01M | $169.90K | $42.66K |
| Interest Expense | $- | $- | $1.01M | $- | $- |
| Depreciation and Amortization | $- | $352.08K | $796.79K | $159.07K | $79.31K |
| EBITDA | $-64.07B | $-58.06M | $-51.47M | $-33.68M | $-17.00M |
| EBITDA Ratio | - | - | -16238.30% | -1619.46% | -735.58% |
| Operating Income | $-64.07B | $-58.41M | $-51.74M | $-33.89M | $-17.08M |
| Operating Income Ratio | - | - | -16325.77% | -1629.17% | -739.01% |
| Total Other Income Expenses Net | $3.03B | $4.94M | $1.23M | $42.84K | $42.66K |
| Income Before Tax | $-61.04B | $-53.47M | $-50.51M | $-33.84M | $-17.04M |
| Income Before Tax Ratio | - | - | -15937.29% | -1627.11% | -737.17% |
| Income Tax Expense | $- | $- | $-1.23M | $-307.49K | $-84.34K |
| Net Income | $-61.04B | $-53.47M | $-49.28M | $-33.54M | $-17.04M |
| Net Income Ratio | - | - | -15548.66% | -1612.33% | -737.17% |
| EPS | $-2035.80 | $-1.88 | $-1.87 | $-1.27 | $-0.67 |
| EPS Diluted | $-2035.80 | $-1.88 | $-1.87 | $-1.27 | $-0.67 |
| Weighted Average Shares Outstanding | 29.98M | 28.42M | 26.39M | 26.32M | 25.51M |
| Weighted Average Shares Outstanding Diluted | 29.98M | 28.42M | 26.39M | 26.32M | 25.51M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $-94.42M | $- | $94.42M | $- | $456 | $38.38K | $94.42K | $183.70K | $189.59K | $482.13K | $660.04K | $748.20K | $665.08K | $682.57K | $480.83K | $483.05K |
| Cost of Revenue | $- | $- | $175.48K | $187.68K | $185.22K | $195.78K | $193.51K | $189.63K | $157.96M | $19.34K | $47.93K | $90.85K | $206.22K | $219.00K | $319.00K | $409.16K | $473.32K | $315.00K | $237.00K | $255.03K |
| Gross Profit | $- | $- | $-175.48K | $-187.68K | $-94.60M | $-195.78K | $94.23M | $-189.63K | $-157.96M | $19.04K | $46.49K | $92.85K | $-16.63K | $263.13K | $341.04K | $339.04K | $191.75K | $367.57K | $243.84K | $228.02K |
| Gross Profit Ratio | - | 0.00% | - | - | - | - | 99.80% | - | -34641101.32% | 49.60% | 49.23% | 50.55% | -8.77% | 54.58% | 51.67% | 45.31% | 28.83% | 53.85% | 50.71% | 47.21% |
| Research and Development Expenses | $14.86M | $11.25M | $10.65M | $11.14M | $11.91M | $10.05M | $9.45M | $10.21M | $9.87M | $9.36M | $7.98M | $9.06M | $7.95M | $6.21M | $6.99M | $5.39M | $4.89M | $4.07M | $3.22M | $2.82M |
| General and Administrative Expenses | $3.69M | $4.01M | $4.25M | $4.12M | $4.38M | $3.87M | $4.04M | $4.46M | $4.11M | $3.84M | $3.70M | $3.95M | $3.15M | $2.60M | $1.34M | $1.18M | $1.14M | $699.00K | $629.00K | $643.98K |
| Selling and Marketing Expenses | $- | $- | $- | $-119.36K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.69M | $4.01M | $4.25M | $4.00M | $4.38M | $3.87M | $4.04M | $4.46M | $4.11M | $3.84M | $3.70M | $3.95M | $3.15M | $2.60M | $1.34M | $1.18M | $1.14M | $699.00K | $629.00K | $643.98K |
| Other Expenses | $6.99K | $7.32K | $-167.69K | $213.04K | $464.35K | $7.32K | $150.19K | $7.32K | $7.32K | $7.32K | $-24.05K | $8.10K | $-118.97K | $-8.09K | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $18.56M | $15.27M | $14.74M | $15.14M | $16.30M | $13.93M | $13.51M | $14.68M | $13.99M | $13.21M | $11.69M | $13.02M | $11.10M | $8.81M | $8.33M | $6.58M | $6.03M | $4.77M | $3.85M | $3.47M |
| Cost and Expenses | $18.56M | $15.27M | $14.91M | $15.33M | $16.30M | $13.93M | $13.51M | $14.68M | $13.99M | $13.23M | $11.74M | $13.11M | $11.31M | $9.03M | $8.65M | $6.98M | $6.50M | $5.08M | $4.09M | $3.72M |
| Interest Income | $415.24K | $547.07K | $826.10K | $804.88K | $754.14K | $855.53K | $1.17M | $831.27K | $516.17K | $222.99K | $142.80K | $132.51K | $142.88K | $17.40K | $3.26K | $6.36K | $518 | $1.15K | $2.47K | $38.49K |
| Interest Expense | $- | $- | $- | $- | $1.08B | $- | $- | $- | $516.17K | $222.99K | $- | $132.51K | $3.56M | $- | $3.26K | $- | $- | $- | $2.47K | $- |
| Depreciation and Amortization | $93.43K | $96.27K | $97.85K | $187.68K | $185.22K | $195.78K | $193.51K | $189.63K | $189.28K | $204.53K | $202.36K | $200.63K | $52.50K | $37.57K | $35.11K | $33.89K | $32.21K | $15.88K | $15.99K | $15.23K |
| EBITDA | $-18.47M | $-15.18M | $-14.82M | $-15.23M | $-14.90M | $-13.84M | $-13.42M | $-14.60M | $-13.90M | $-13.11M | $-11.58M | $-12.70M | $-11.04M | $-8.50M | $-7.95M | $-6.20M | $-5.76M | $-4.38M | $-3.59M | $-3.22M |
| EBITDA Ratio | - | - | - | - | - | - | -14.21% | - | -3048427.41% | -34165.60% | -12268.90% | -6911.21% | -5822.71% | -1762.29% | -1204.86% | -828.09% | -866.33% | -642.16% | -746.24% | -667.42% |
| Operating Income | $-18.56M | $-15.27M | $-14.91M | $-15.33M | $-16.30M | $-13.93M | $-13.50M | $-14.68M | $-13.99M | $-13.19M | $-11.65M | $-12.93M | $-11.12M | $-8.54M | $-7.99M | $-6.24M | $-5.84M | $-4.40M | $-3.61M | $-3.24M |
| Operating Income Ratio | - | - | - | - | - | - | -14.30% | - | -3066887.50% | -34361.95% | -12334.43% | -7036.44% | -5863.02% | -1772.01% | -1210.67% | -833.47% | -877.56% | -644.66% | -750.08% | -670.58% |
| Total Other Income Expenses Net | $506.34K | $676.38K | $833.82K | $1.02M | $1.22M | $1.33M | $1.32M | $1.08M | $739.45K | $343.85K | $118.75K | $29.15K | $23.91K | $9.31K | $3.26K | $6.36K | $347 | $910 | $2.87K | $38.49K |
| Income Before Tax | $-18.05M | $-14.60M | $-14.08M | $-14.31M | $-15.08M | $-12.60M | $-12.19M | $-13.60M | $-13.25M | $-12.84M | $-11.53M | $-12.90M | $-11.09M | $-8.53M | $-7.99M | $-6.23M | $-5.84M | $-4.40M | $-3.60M | $-3.20M |
| Income Before Tax Ratio | - | - | - | - | - | - | -12.91% | - | -2904728.51% | -33466.12% | -12208.52% | -7020.49% | -5850.41% | -1770.09% | -1210.12% | -832.62% | -877.50% | -644.52% | -749.48% | -662.61% |
| Income Tax Expense | $- | $419 | $-473 | $-1 | $-754.66K | $-13.91B | $-1.14M | $-1.08B | $-740.06K | $-343.79K | $-52.39K | $-29.42K | $-307.49K | $-17.46K | $796 | $- | $42.31K | $-480 | $806 | $- |
| Net Income | $-18.05M | $-14.60M | $-14.08M | $-14.31M | $-15.08M | $-12.60M | $-12.19M | $1.06B | $-12.51M | $-12.50M | $-11.53M | $-12.87M | $-10.78M | $-8.53M | $-7.99M | $-6.23M | $-5.84M | $-4.40M | $-3.60M | $-3.20M |
| Net Income Ratio | - | - | - | - | - | - | -12.91% | - | -2742434.65% | -32570.38% | -12208.67% | -7004.48% | -5688.22% | -1770.08% | -1210.18% | -832.62% | -877.48% | -644.49% | -749.56% | -662.61% |
| EPS | $-0.60 | $-0.49 | $-0.47 | $-0.49 | $-0.52 | $-0.43 | $-0.43 | $40.16 | $-0.47 | $-0.47 | $-0.44 | $-0.49 | $-0.42 | $-0.47 | $-0.33 | $-0.46 | $-0.43 | $-0.33 | $-0.27 | $-0.24 |
| EPS Diluted | $-0.60 | $-0.49 | $-0.47 | $-0.49 | $-0.52 | $-0.43 | $-0.43 | $40.16 | $-0.47 | $-0.47 | $-0.44 | $-0.49 | $-0.42 | $-0.47 | $-0.33 | $-0.46 | $-0.43 | $-0.33 | $-0.27 | $-0.24 |
| Weighted Average Shares Outstanding | 29.98M | 29.84M | 29.65M | 29.37M | 29.27M | 29.27M | 28.65M | 26.44M | 26.41M | 26.39M | 26.39M | 26.36M | 25.98M | 18.29M | 23.89M | 13.51M | 13.51M | 13.51M | 13.51M | 13.51M |
| Weighted Average Shares Outstanding Diluted | 29.98M | 29.84M | 29.65M | 29.37M | 29.27M | 29.27M | 28.65M | 26.44M | 26.41M | 26.39M | 26.39M | 26.36M | 25.98M | 18.29M | 23.89M | 13.51M | 13.51M | 13.51M | 13.51M | 13.51M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $36.14B | $59.41M | $72.64M | $74.89M | $37.09M |
| Short Term Investments | $- | $26.26M | $32.89M | $74.31M | $- |
| Cash and Short Term Investments | $36.14B | $85.67M | $105.52M | $149.20M | $37.09M |
| Net Receivables | $- | $- | $12.42K | $246.04K | $500.11K |
| Inventory | $- | $- | $1 | $- | $- |
| Other Current Assets | $3.44B | $3.42M | $3.21M | $2.89M | $140.96K |
| Total Current Assets | $39.59B | $89.08M | $108.75M | $152.33M | $37.73M |
| Property Plant Equipment Net | $4.79B | $5.40M | $5.78M | $6.13M | $677.47K |
| Goodwill | $6.69M | $6.69M | $6.69M | $6.70M | $- |
| Intangible Assets | $350.41K | $379.68K | $408.95K | $439.00K | $- |
| Goodwill and Intangible Assets | $7.04B | $7.07M | $7.10M | $7.14M | $- |
| Long Term Investments | $- | $- | $- | $996.56K | $- |
| Tax Assets | $- | $- | $- | $- | $46.26K |
| Other Non-Current Assets | $1.30B | $1.03M | $743.70K | $102.13K | $-31.92K |
| Total Non-Current Assets | $13.13B | $13.50M | $13.62M | $14.37M | $691.80K |
| Other Assets | $- | $1 | $- | $- | $- |
| Total Assets | $52.71B | $102.58M | $122.37M | $166.70M | $38.42M |
| Account Payables | $1.96M | $2.11M | $3.15M | $1.39M | $1.48M |
| Short Term Debt | $338.44K | $300.11K | $378.72K | $274.04K | $76.32K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $7.50B | $5.43M | $4.52M | $3.97M | $698.99K |
| Total Current Liabilities | $7.50B | $7.85M | $8.05M | $5.63M | $2.26M |
| Long Term Debt | $3.83B | $4.16M | $4.46M | $5.09M | $544.77K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-46.26K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $46.26K |
| Other Non-Current Liabilities | $-3.82M | $- | $- | $- | $58.10M |
| Total Non-Current Liabilities | $3.82B | $4.16M | $4.46M | $5.09M | $58.65M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $11.33B | $12.01M | $12.52M | $10.72M | $60.90M |
| Preferred Stock | $- | $- | $122.37B | $166.70B | $58.10M |
| Common Stock | $31.05K | $29.27K | $26.42K | $26.32K | $4.95K |
| Retained Earnings | $-224.30B | $-163.26M | $-109.79M | $-59.27M | $-25.74M |
| Accumulated Other Comprehensive Income Loss | $- | $-778 | $-30.12K | $-49.01K | $-58.10M |
| Other Total Stockholders Equity | $265.68B | $253.81M | $-122.15B | $-166.49B | $61.36M |
| Total Stockholders Equity | $41.39B | $90.58M | $109.85M | $155.98M | $-22.48M |
| Total Equity | $41.39B | $90.58M | $109.85M | $155.98M | $-22.48M |
| Total Liabilities and Stockholders Equity | $52.71B | $102.58M | $122.37M | $166.70M | $38.42M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $52.71B | $102.58M | $122.37M | $166.70M | $38.42M |
| Total Investments | $- | $26.26M | $32.89M | $75.31M | $- |
| Total Debt | $4.16B | $4.46M | $4.84M | $5.36M | $621.09K |
| Net Debt | $-31.98B | $-54.94M | $-67.80M | $-69.52M | $-36.47M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $36.14M | $45.21M | $59.73M | $66.29M | $59.41M | $68.04M | $104.02M | $77.43M | $72.64M | $76.42M | $87.94M | $75.21M | $74.89M | $106.93M | $50.25M | $30.93M | $37.09M | $-13.78M |
| Short Term Investments | $- | $5.45M | $- | $4.99M | $26.26M | $29.20M | $4.97M | $14.11M | $32.89M | $40.78M | $40.16M | $62.57M | $74.31M | $42.55M | $- | $- | $- | $27.56M |
| Cash and Short Term Investments | $36.14M | $50.66M | $59.73M | $71.28M | $85.67M | $97.24M | $108.99M | $91.54M | $105.52M | $117.20M | $128.10M | $137.77M | $149.20M | $149.48M | $50.25M | $30.93M | $37.09M | $13.78M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $1.05K | $12.42K | $70.18K | $178.43K | $279.61K | $246.04K | $471.38K | $495.11K | $492.40K | $500.11K | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $1 | $1 | $- | $1 | $- | $1 | $- | $- |
| Other Current Assets | $3.44M | $- | $3.96M | $3.17M | $3.42M | $3.34M | $2.52M | $2.70M | $3.21M | $2.76M | $890.41K | $1.48M | $2.89M | $3.36M | $696.68K | $756.60K | $140.96K | $- |
| Total Current Assets | $39.59M | $55.26M | $63.69M | $74.45M | $89.08M | $100.58M | $111.51M | $94.23M | $108.75M | $120.02M | $129.17M | $139.53M | $152.33M | $153.31M | $51.44M | $32.18M | $37.73M | $13.78M |
| Property Plant Equipment Net | $4.79M | $4.95M | $5.12M | $5.25M | $5.40M | $5.48M | $5.56M | $5.63M | $5.78M | $5.82M | $5.68M | $5.71M | $6.13M | $618.63K | $644.85K | $660.14K | $677.47K | $- |
| Goodwill | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.69M | $6.70M | $- | $- | $- | $- | $- |
| Intangible Assets | $350.41K | $357.73K | $365.05K | $372.36K | $379.68K | $387.00K | $394.31K | $401.63K | $408.95K | $416.26K | $423.58K | $430.90K | $439.00K | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $7.04M | $7.05M | $7.06M | $7.06M | $7.07M | $7.08M | $7.08M | $7.09M | $7.10M | $7.11M | $7.11M | $7.12M | $7.14M | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $4.96B | $14.09B | $- | $- | $- | $- | $996.56K | $10.10M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $-4.96B | $-14.09B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.30M | $1.30M | $1.23M | $1.22M | $1.03M | $743.70K | $743.70K | $743.70K | $743.70K | $737.29K | $89.58K | $89.58K | $102.13K | $14.33K | $960.39K | $14.33K | $14.33K | $-13.78M |
| Total Non-Current Assets | $13.13M | $13.30M | $13.40M | $13.54M | $13.50M | $13.30M | $13.39M | $13.46M | $13.62M | $13.67M | $12.88M | $12.92M | $14.37M | $10.73M | $1.61M | $674.47K | $691.80K | $-13.78M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $52.71M | $68.56M | $77.09M | $87.98M | $102.58M | $113.88M | $124.90M | $107.70M | $122.37M | $133.69M | $142.05M | $152.45M | $166.70M | $164.04M | $53.04M | $32.86M | $38.42M | $- |
| Account Payables | $1.96M | $1.94M | $2.62M | $2.27M | $2.11M | $1.94M | $2.69M | $2.72M | $3.15M | $2.34M | $1.24M | $1.64M | $1.39M | $1.80M | $1.43M | $1.37M | $1.48M | $- |
| Short Term Debt | $338.44K | $324.70K | $311.46K | $298.54K | $300.11K | $301.63K | $332.68K | $363.24K | $378.72K | $308.69K | $286.37K | $265.42K | $274.04K | $82.80K | $80.61K | $78.45K | $76.32K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $5.17M | $- | $2.43M | $- | $- | $- | $2.23M | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $5.21M | $4.65M | $3.85M | $2.61M | $5.43M | $3.38M | $2.45M | $2.44M | $4.52M | $4.61M | $2.27M | $1.77M | $3.97M | $3.39M | $3.32M | $1.31M | $698.99K | $- |
| Total Current Liabilities | $7.50M | $6.92M | $6.78M | $5.18M | $7.85M | $5.62M | $5.48M | $5.53M | $8.05M | $7.26M | $3.80M | $3.67M | $5.63M | $5.27M | $4.83M | $2.76M | $2.26M | $- |
| Long Term Debt | $3.82M | $3.92M | $4.00M | $4.08M | $4.16M | $4.24M | $4.31M | $4.38M | $4.46M | $4.54M | $4.64M | $4.71M | $5.09M | $481.96K | $503.21K | $524.14K | $544.77K | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $9.90K | $9.90K | $- | $- | $82.89M | $- | $58.10M | $- |
| Total Non-Current Liabilities | $3.82M | $3.92M | $4.00M | $4.08M | $4.16M | $4.24M | $4.31M | $4.38M | $4.46M | $4.54M | $4.65M | $4.72M | $5.09M | $481.96K | $83.40M | $524.14K | $58.65M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $11.33M | $10.84M | $10.78M | $9.26M | $12.01M | $9.86M | $9.79M | $9.91M | $12.52M | $11.80M | $8.46M | $8.39M | $10.72M | $5.75M | $88.23M | $3.28M | $60.90M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $164.04B | $61.77B | $58.10M | $58.10M | $16.61M |
| Common Stock | $31.05K | $31.05K | $29.65K | $29.65K | $29.27K | $29.27K | $29.26K | $26.50K | $26.42K | $26.41K | $26.39K | $26.38K | $26.32K | $25.94K | $5.28K | $13.51K | $4.95K | $- |
| Retained Earnings | $-224.30M | $-206.24M | $-191.65M | $-177.57M | $-163.26M | $-148.18M | $-135.58M | $-123.39M | $-109.79M | $-96.54M | $-83.70M | $-72.17M | $-59.27M | $-48.49M | $-39.95M | $-31.97M | $-25.74M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $7.84K | $- | $-1.08K | $-778 | $5.61K | $-2.22K | $506 | $-30.12K | $-142.47K | $-181.56K | $-167.40K | $-49.01K | $-4.75K | $-149.42B | $-58.10M | $-58.10M | $-6.53M |
| Other Total Stockholders Equity | $265.65M | $263.93M | $257.92M | $256.26M | $253.81M | $252.16M | $250.66M | $221.15M | $219.64M | $218.55M | $217.45M | $216.37M | $215.28M | $-163.84B | $4.76M | $119.64M | $61.36M | $- |
| Total Stockholders Equity | $41.39M | $57.72M | $66.31M | $78.72M | $90.58M | $104.02M | $115.10M | $97.79M | $109.85M | $121.89M | $133.59M | $144.06M | $155.98M | $158.29M | $-35.19M | $29.57M | $-22.48M | $10.08M |
| Total Equity | $41.39M | $57.72M | $66.31M | $78.72M | $90.58M | $104.02M | $115.10M | $97.79M | $109.85M | $121.89M | $133.59M | $144.06M | $155.98M | $158.29M | $-35.19M | $29.57M | $-22.48M | $10.08M |
| Total Liabilities and Stockholders Equity | $52.71M | $68.56M | $77.09M | $87.98M | $102.58M | $113.88M | $124.90M | $107.70M | $122.37M | $133.69M | $142.05M | $152.45M | $166.70M | $164.04M | $53.04M | $32.86M | $38.42M | $10.08M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $52.71M | $68.56M | $77.09M | $87.98M | $102.58M | $113.88M | $124.90M | $107.70M | $122.37M | $133.69M | $142.05M | $152.45M | $166.70M | $164.04M | $53.04M | $32.86M | $38.42M | $10.08M |
| Total Investments | $- | $5.45M | $- | $4.99M | $26.26M | $29.20M | $4.97B | $14.11B | $32.89M | $40.78M | $40.16M | $62.57M | $74.31M | $52.65M | $- | $- | $- | $27.56M |
| Total Debt | $4.16M | $4.24M | $4.31M | $4.38M | $4.46M | $4.54M | $4.64M | $4.74M | $4.84M | $4.85M | $4.93M | $4.97M | $5.36M | $564.76K | $583.82K | $602.59K | $621.09K | $- |
| Net Debt | $-31.98M | $-40.96M | $-55.42M | $-61.91M | $-54.94M | $-63.50M | $-99.37M | $-72.69M | $-67.80M | $-71.57M | $-83.01M | $-70.23M | $-69.52M | $-106.36M | $-49.66M | $-30.33M | $-36.47M | $13.78M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-61.04M | $-53.47M | $-50.51M | $-33.54M | $-17.04M |
| Depreciation and Amortization | $- | $352.08K | $796.79K | $159.07K | $79.31K |
| Deferred Income Tax | $- | $- | $- | $-307.49K | $-349.96K |
| Stock Based Compensation | $6.50M | $5.73M | $4.06M | $1.80M | $1.09M |
| Change in Working Capital | $-925.38K | $-974.64K | $1.72M | $900.42K | $1.25M |
| Accounts Receivables | $- | $12.42K | $233.62K | $279.71K | $-290.17K |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-112.14K | $-1.11M | $1.76M | $-130.40K | $1.19M |
| Other Working Capital | $-813.24K | $119.84K | $-276.56K | $751.10K | $357.58K |
| Other Non Cash Items | $461.05K | $-601.59K | $-166.21K | $130.24K | $349.96K |
| Net Cash Provided by Operating Activities | $-55.00M | $-48.97M | $-44.10M | $-30.85M | $-14.62M |
| Investments in Property Plant and Equipment | $- | $-342.75K | $-742.48K | $-60.79K | $-53.41K |
| Acquisitions Net | $- | $- | $-41.83M | $70.35K | $- |
| Purchases of Investments | $- | $-44.66M | $-50.10M | $-75.63M | $- |
| Sales Maturities of Investments | $- | $52.30M | $92.68M | $75.62M | $- |
| Other Investing Activities | $26.43M | $- | $41.83M | $-75.62M | $- |
| Net Cash Used for Investing Activities | $26.43M | $7.30M | $41.83M | $-75.62M | $-53.41K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $4.24M | $28.20M | $19.00K | $120.32M | $37.98M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.30M | $241.07K | $19.00K | $23.95M | $37.98M |
| Net Cash Used Provided by Financing Activities | $5.30M | $28.44M | $19.00K | $144.26M | $37.98M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-23.26M | $-13.23M | $-2.25M | $37.80M | $23.31M |
| Cash at End of Period | $36.14M | $59.41M | $72.64M | $74.89M | $37.09M |
| Cash at Beginning of Period | $59.41M | $72.64M | $74.89M | $37.09M | $13.78M |
| Operating Cash Flow | $-55.00M | $-48.97M | $-44.10M | $-30.85M | $-14.62M |
| Capital Expenditure | $-84.88K | $-342.75K | $-742.48K | $-60.79K | $-53.41K |
| Free Cash Flow | $-55.08M | $-49.31M | $-44.84M | $-30.91M | $-14.67M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-18.05M | $-14.60M | $-14.08M | $-14.31M | $-15.08M | $-12.60M | $-12.19M | $-13.60M | $-13.25M | $-12.84M | $-11.53M | $-12.90M | $-10.78M | $-8.53M | $-7.99M | $-6.23M | $-5.84M | $-4.40M | $-3.60M | $-3.20M |
| Depreciation and Amortization | $93.43K | $96.27K | $97.85K | $187.68K | $97.07K | $85.61K | $-20.23K | $189.63K | $189.28K | $204.53K | $-82.94K | $200.63K | $52.50K | $37.57K | $35.11K | $33.89K | $32.21K | $15.88K | $15.99K | $15.23K |
| Deferred Income Tax | $- | $- | $- | $- | $-620.19K | $620.19K | $- | $- | $- | $- | $- | $- | $-13.51M | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.72M | $1.64M | $1.66M | $1.47M | $1.64M | $1.48M | $1.33M | $1.27M | $1.05M | $1.07M | $1.05M | $897.65K | $632.58K | $636.81K | $351.01K | $182.22K | $216.61K | $310.46K | $287.55K | $272.14K |
| Change in Working Capital | $1.69M | $-657.59K | $724.49K | $-2.68M | $1.88M | $-794.68K | $27.06K | $-2.09M | $473.70K | $1.05M | $782.34K | $-586.47K | $1.05M | $-1.18M | $1.16M | $-126.31K | $134.00K | $586.71K | $-66.68K | $598.97K |
| Accounts Receivables | $- | $- | $- | $- | $-12.42K | $- | $1.05K | $11.37K | $57.76K | $108.25K | $101.19K | $-33.57K | $250.98K | $23.73K | $-2.70K | $7.71K | $78.03K | $-278.19K | $48.95K | $-138.97K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $194.04K | $-149.61M | $- | $-29.45M | $- | $- | $- | $-29.56M |
| Accounts Payables | $56.74K | $-679.45K | $393.18K | $117.39K | $170.57K | $-778.20K | $-68.33K | $-430.93K | $816.18K | $1.10M | $-402.12K | $248.02K | $-445.01K | $362.64K | $63.72K | $-111.74K | $274.07K | $309.64K | $-267.57K | $869.45K |
| Other Working Capital | $1.64M | $21.86K | $331.31K | $-2.80M | $1.71M | $-16.48K | $94.34K | $-1.67M | $-400.24K | $-158.68K | $1.08M | $-800.92K | $1.05M | $148.04M | $1.10M | $29.42M | $-218.10K | $555.25K | $151.94K | $29.42M |
| Other Non Cash Items | $30.99K | $46.55K | $69.92K | $1.57M | $-313.03K | $-822.00K | $99.55K | $-186.30K | $-214.19K | $-96.46K | $-220.73K | $103.53K | $13.33M | $8.55K | $360.21K | $354.05K | $273.84K | $309.64K | $-267.57K | $869.45K |
| Net Cash Provided by Operating Activities | $-14.51M | $-13.47M | $-11.53M | $-15.49M | $-11.78M | $-12.03M | $-10.75M | $-14.42M | $-11.75M | $-10.62M | $-9.45M | $-12.28M | $-9.24M | $-9.03M | $-6.44M | $-6.14M | $-5.45M | $-3.49M | $-3.37M | $-2.31M |
| Investments in Property Plant and Equipment | $-9.36K | $-5.27K | $-32.77K | $-37.48K | $-170.92K | $-57.15K | $-86.69K | $-27.99K | $-69.30K | $-393.13K | $-165.00K | $-115.05K | $-13.05K | $-11.35K | $-19.82K | $-16.56K | $-38.06K | $-5.60K | $-5.40K | $-4.35K |
| Acquisitions Net | $- | $- | $- | $- | $-3.30M | $23.91M | $- | $- | $-41.83M | $486.94K | $- | $- | $70.35K | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $-15.75M | $-28.91M | $- | $- | $-12.38M | $-19.74M | $-10.01M | $-7.98M | $-22.87M | $-52.76M | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $5.50M | $- | $5.00M | $21.43M | $19.05M | $5.00M | $9.25M | $19.00M | $20.60M | $19.25M | $32.33M | $20.50M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-5.41M | $- | $21.43M | $3.30M | $-23.91M | $9.25M | $19.00M | $41.83M | $-486.94K | $22.32M | $12.52M | $70.35K | $-52.76M | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $5.49M | $-5.42M | $4.97M | $21.39M | $3.13M | $-23.97M | $9.16M | $18.97M | $8.15M | $-880.08K | $22.15M | $12.40M | $-22.81M | $-52.77M | $-19.82K | $-16.56K | $-38.06K | $-5.60K | $-5.40K | $-4.35K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $4.24M | $- | $979.92K | $7.83K | $21.45K | $28.17M | $239.41M | $-184.68K | $-17.21K | $27.78K | $193.11K | $7.52K | $118.49M | $25.77M | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-40.99K | $127.19K | $- | $979.92K | $7.83K | $21.45K | $28.17M | $239.41K | $-184.68K | $-17.21K | $27.78K | $193.11K | $7.52K | $118.49M | $25.77M | $- | $36.98M | $- | $- | $998.31K |
| Net Cash Used Provided by Financing Activities | $-40.99K | $4.36M | $- | $979.92K | $7.83K | $21.45K | $28.17M | $239.41K | $-184.68K | $-17.21K | $27.78K | $193.11K | $7.52K | $118.49M | $25.77M | $- | $36.98M | $- | $- | $998.31K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-36.80M | $36.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-9.06M | $-14.52M | $-6.56M | $6.88M | $-8.63M | $-35.98M | $26.59M | $4.79M | $-3.78M | $-11.52M | $12.73M | $316.92K | $-32.04M | $56.68M | $19.31M | $-6.16M | $31.49M | $-3.49M | $-3.37M | $-1.32M |
| Cash at End of Period | $36.14M | $45.21M | $59.73M | $66.29M | $59.41M | $68.04M | $104.02M | $77.43M | $72.64M | $76.42M | $87.94M | $75.21M | $74.89M | $106.93M | $50.25M | $30.93M | $37.09M | $5.60M | $9.09M | $12.46M |
| Cash at Beginning of Period | $45.21M | $59.73M | $66.29M | $59.41M | $68.04M | $104.02M | $77.43M | $72.64M | $76.42M | $87.94M | $75.21M | $74.89M | $106.93M | $50.25M | $30.93M | $37.09M | $5.60M | $9.09M | $12.46M | $13.78M |
| Operating Cash Flow | $-14.51M | $-13.47M | $-11.53M | $-15.49M | $-11.78M | $-12.03M | $-10.75M | $-14.42M | $-11.75M | $-10.62M | $-9.45M | $-12.28M | $-9.24M | $-9.03M | $-6.44M | $-6.14M | $-5.45M | $-3.49M | $-3.37M | $-2.31M |
| Capital Expenditure | $-9.36K | $-5.27K | $-32.77K | $-37.48K | $-170.92K | $-57.15K | $-86.69K | $-27.99K | $-69.30K | $-393.13K | $-165.00K | $-115.05K | $-13.05K | $-11.35K | $-19.82K | $-16.56K | $-38.06K | $-5.60K | $-5.40K | $-4.35K |
| Free Cash Flow | $-14.52M | $-13.48M | $-11.56M | $-15.53M | $-11.95M | $-12.08M | $-10.84M | $-14.45M | $-11.82M | $-11.02M | $-9.61M | $-12.40M | $-9.25M | $-9.05M | $-6.46M | $-6.16M | $-5.49M | $-3.49M | $-3.37M | $-2.32M |
Immuneering Dividends
Explore Immuneering's dividend history, including dividend yield, payout ratio, and historical payments.
Immuneering News
Read the latest news about Immuneering, including recent articles, headlines, and updates.
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company's pipeline, platform, and business strategy.
Immuneering Corporation Announces Grant of Inducement Award
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on March 20, 2025, that Igor Matushansky, M.D.
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Additional IMM-1-104 Phase 2a data updates and initiation of new IMM-1-104 combination arms expected in 2025; planning underway for potential IMM-1-104 global pivotal trial - - Named industry veteran Dr. Igor Matushansky as Chief Medical Officer - - Cash runway extended into 2026 - CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates.
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushansky, MD, PhD, has joined the company as Chief Medical Officer.
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company's pipeline, platform, and business strategy.
Immuneering Launches Pancreatic Cancer Advisory Board
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board.
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd.
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1 based immune checkpoint inhibitors.
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company's pipeline, platform, and business strategy.
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer - - Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End - - Cash Runway into Fourth Quarter 2025 - CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided business updates.
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 - - Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer - - Preclinical Data Presented at AACR Demonstrates that Combining IMM-1-104 with Chemotherapies Used in the Treatment of First-line Pancreatic Cancer Yields Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - Initial PK, PD and Safety Data from Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations expected in 2H 2024 - CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided business updates.
Why is Immuneering (IMRX) Stock Up 24% Today?
Various names in the biotech sector are seeing big moves in today's session, as investors are clearly interested in rotation into a number of higher-growth small-cap stocks. Immuneering (NASDAQ: IMRX ) is certainly one such company generating outsized interest today.
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104's path to U.S. FDA submission for PDAC - - Phase 2a trial of IMM-1-104 includes multiple arms open to first-line pancreatic cancer patients, as well as arms open to patients with second-line pancreatic cancer, RAS-mutant melanoma, and RAS-mutant lung cancer - - Company expects initial data from multiple arms of its Phase 2a clinical trial in the second half of 2024 - CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC).
Immuneering to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company's pipeline, platform, and business strategy.
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided business updates.
Immuneering Recognizes Melanoma Awareness Month
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of IMM-6-415 in patients with advanced solid tumors harboring RAF or RAS mutations - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, recognizes the importance of early detection and treatment during Melanoma Awareness Month, and highlights RAS mutant melanoma as the focus of one of the five arms in its ongoing Phase 2a clinical study for its lead program IMM-1-104.
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone - - Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024, to discuss the company's pipeline, platform, and business strategy.
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1 portion of the Phase 1/2a trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of IMM-6-415 and establish a candidate recommended Phase 2 dose (RP2D) - -Initial PK, PD and safety data expected in 2024 - CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or RAS mutations.
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, supporting goal of Universal-RAS activity - - Target lesion regression observed in over half of patients treated with IMM-1-104 at 320mg or 240mg QD, with best individual lesion regression of -35.7% and best RECIST sum of longest diameters (SLD) of -18.9%, both at 320mg - - Candidate RP2D of 320 mg QD supported by tolerability, PK/PD, ctDNA results & initial anti-tumor activity - - Phase 2a portion of the study underway with three monotherapy and two combination arms in earlier lines of treatment, with initial data from multiple arms expected in 2024 - - Immuneering will host an investor call today at 8:30 a.m. ET. - CAMBRIDGE, Mass.
Immuneering Appoints Thomas J. Schall, Ph.D.
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J.
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for IMRX.